Sanofi (NASDAQ:SNY) Releases Earnings Results, Misses Estimates By $0.06 EPS

Key Points

• Sanofi reported a quarterly earnings per share (EPS) of $0.90, which missed analysts' expectations by $0.06, while revenue was significantly higher than estimates at $11.34 billion.
• The company experienced a 7.0% decline in revenue compared to the same quarter last year, with the prior year's EPS at $1.73.
• Despite the earnings miss, several analysts maintain an "overweight" or "buy" rating on Sanofi's stock, with a consensus target price of $62.00.

Sanofi (NASDAQ:SNY - Get Free Report) announced its quarterly earnings data on Thursday. The company reported $0.90 EPS for the quarter, missing the consensus estimate of $0.96 by ($0.06), Zacks reports. Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The business had revenue of $11.34 billion for the quarter, compared to analyst estimates of $9.91 billion. During the same quarter in the previous year, the firm posted $1.73 earnings per share. The business's revenue was down 7.0% on a year-over-year basis.

Sanofi Stock Down 3.5%

NASDAQ SNY traded down $1.66 on Wednesday, reaching $46.18. The company had a trading volume of 3,486,814 shares, compared to its average volume of 2,580,158. The firm has a market capitalization of $113.40 billion, a PE ratio of 11.10, a P/E/G ratio of 1.15 and a beta of 0.48. Sanofi has a 1 year low of $44.73 and a 1 year high of $60.12. The firm has a 50-day moving average of $48.93 and a 200-day moving average of $52.06. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.94.

Hedge Funds Weigh In On Sanofi

Institutional investors and hedge funds have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Sanofi by 1.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,255 shares of the company's stock valued at $2,732,000 after buying an additional 752 shares during the last quarter. AQR Capital Management LLC raised its position in shares of Sanofi by 107.2% during the 1st quarter. AQR Capital Management LLC now owns 30,518 shares of the company's stock valued at $1,693,000 after acquiring an additional 15,791 shares in the last quarter. Finally, Brighton Jones LLC raised its position in shares of Sanofi by 52.6% during the 4th quarter. Brighton Jones LLC now owns 5,420 shares of the company's stock valued at $261,000 after acquiring an additional 1,869 shares in the last quarter. Hedge funds and other institutional investors own 14.04% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on SNY. Guggenheim reiterated a "buy" rating on shares of Sanofi in a research report on Tuesday, June 3rd. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Sanofi in a research report on Tuesday. Morgan Stanley set a $56.00 target price on shares of Sanofi in a research report on Monday, June 2nd. BNP Paribas began coverage on shares of Sanofi in a report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price objective for the company. Finally, Barclays reissued an "overweight" rating on shares of Sanofi in a report on Wednesday, July 2nd. Two research analysts have rated the stock with a hold rating, four have issued a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $62.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.